Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer

Harandi, A., Zaidi, A. S., Stocker, A. M., & Laber, D. A. (2009). Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. Journal of Oncology, 2009(), 509-522. https://doi.org/10.1155/2009/567486
Wind, N. S., & Holen, I. (2011). Multidrug Resistance in Breast Cancer: From In Vitro Models to Clinical Studies. International Journal of Breast Cancer, 2011(), 294-305. https://doi.org/10.4061/2011/967419
Peddi, P. F., Ellis, M. J., & Ma, C. (2012). Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy. International Journal of Breast Cancer, 2012(), 64-70. https://doi.org/10.1155/2012/217185
Larsen, M. J., Thomassen, M., Gerdes, A. M., & Kruse, T. A. (2014). Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics. Breast Cancer: Basic and Clinical Research, (2014), 145-155. https://doi.org/10.4137/BCBCR.S18715
Dragovich, T., & Campen, C. (2009). Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. Journal of Oncology, 2009(), 440-447. https://doi.org/10.1155/2009/804108